Breaking News

Thursday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
CureVac, GSK announce rat model data for second COVID-19 vaccine candidate » 07:56
05/13/21
05/13
07:56
05/13/21
07:56
CVAC

CureVac

$93.89 /

-3.975 (-4.06%)

, GSK

GlaxoSmithKline

$38.34 /

+0.15 (+0.39%)

CureVac (CVAC) announced…

CureVac (CVAC) announced together with its collaboration partner GlaxoSmithKline (GSK), first preclinical data in a rat model, showing that its second-generation COVID-19 vaccine candidate, CV2CoV, induces high levels of antigen production as well as strong and dose-dependent immune responses in vaccinated animals. CV2CoV is a co-development between CureVac and GSK and is based on a new mRNA backbone, which differs from CureVac's first-generation vaccine candidate, CVnCoV, currently in late-stage clinical testing. Preclinical data in rats immunized with CV2CoV in the dose range of 0.5-40microgram demonstrated fast onset of strong immune responses already after the first dose. In addition, the serum of vaccinated animals showed significant cross-neutralization against variants first discovered in Denmark, the UK and South Africa.

ShowHide Related Items >><<
GSK GlaxoSmithKline
$38.34 /

+0.15 (+0.39%)

CVAC CureVac
$93.89 /

-3.975 (-4.06%)

CVAC CureVac
$93.89 /

-3.975 (-4.06%)

04/26/21 Credit Suisse
CureVac assumed with an Underperform at Credit Suisse
04/26/21 Guggenheim
CureVac initiated with a Buy at Guggenheim
01/07/21 Morgan Stanley
CureVac COVID-19 deal provides 'sentiment boost' for Bayer, says Morgan Stanley
12/10/20 Credit Suisse
CureVac downgraded to Underperform on rising valuation at Credit Suisse
GSK GlaxoSmithKline
$38.34 /

+0.15 (+0.39%)

05/11/21 UBS
GlaxoSmithKline price target raised to 1,370 GBp from 1,360 GBp at UBS
04/30/21 Deutsche Bank
GlaxoSmithKline price target raised to 1,200 GBp at Deutsche Bank
04/20/21 Morgan Stanley
GlaxoSmithKline price target lowered to 1,550 GBp at Morgan Stanley
04/20/21 UBS
GlaxoSmithKline price target raised to 1,360 GBp from 1,320 GBp at UBS
GSK GlaxoSmithKline
$38.34 /

+0.15 (+0.39%)

  • 28
    Jan
  • 14
    Aug
GSK GlaxoSmithKline
$38.34 /

+0.15 (+0.39%)

CVAC CureVac
$93.89 /

-3.975 (-4.06%)

GSK GlaxoSmithKline
$38.34 /

+0.15 (+0.39%)

CVAC CureVac
$93.89 /

-3.975 (-4.06%)

GSK GlaxoSmithKline
$38.34 /

+0.15 (+0.39%)

CVAC CureVac
$93.89 /

-3.975 (-4.06%)

Over a week ago
Options
Largest borrow rate increases among liquid names » 08:45
05/10/21
05/10
08:45
05/10/21
08:45
WPRT

Westport

$6.24 /

+0.105 (+1.71%)

, CVAC

CureVac

$100.40 /

+6.34 (+6.74%)

, SEAH

Sports Entertainment Acquisition

$10.14 /

-0.08 (-0.78%)

, GTT

GTT Communications

$1.53 /

+0.04 (+2.68%)

, BGS

B&G Foods

$29.36 /

-0.29 (-0.98%)

, SVXY

ProShares Short VIX Short-Term Futures

$51.97 /

+1.44 (+2.85%)

, NMRD

Nemaura Medical

$8.55 /

-0.245 (-2.79%)

, YALA

Yalla

$20.44 /

+0.35 (+1.74%)

, MNMD

MindMed

$3.28 /

-0.11 (-3.24%)

, EH

Ehang

$23.42 /

+0.03 (+0.13%)

Latest data shows the…

Latest data shows the largest indicative borrow rate increases among liquid option names include: Westport (WPRT) 6.33% +2.22, CureVac (CVAC) 18.87% +1.23, Sports Entertainment Acquisition Corp (SEAH) 2.00% +1.22, GTT Communications (GTT) 77.83% +0.73, B&G Foods (BGS) 3.23% +0.63, ProShares Short VIX Short Term Futures (SVXY) 1.00% +0.49, Nemaura Medical (NMRD) 90.74% +0.45, Yalla Group Limited (YALA) 21.70% +0.32, (MNMD) 26.63% +0.26, and EHang Holdings Ltd (EH) 31.58% +0.20.

ShowHide Related Items >><<
YALA Yalla
$20.44 /

+0.35 (+1.74%)

WPRT Westport
$6.24 /

+0.105 (+1.71%)

SEAH Sports Entertainment Acquisition
$10.14 /

-0.08 (-0.78%)

NMRD Nemaura Medical
$8.55 /

-0.245 (-2.79%)

MNMD MindMed
$3.28 /

-0.11 (-3.24%)

GTT GTT Communications
$1.53 /

+0.04 (+2.68%)

EH Ehang
$23.42 /

+0.03 (+0.13%)

CVAC CureVac
$100.40 /

+6.34 (+6.74%)

BGS B&G Foods
$29.36 /

-0.29 (-0.98%)

WPRT Westport
$6.24 /

+0.105 (+1.71%)

03/18/21 Lake Street
Lake Street confidence in Westport's China ramp boosted by Weichai deal
03/17/21 H.C. Wainwright
Westport price target raised to $16 from $5 at H.C. Wainwright
02/08/21 Craig-Hallum
Clean Energy price target raised to $25 from $12 at Craig-Hallum
02/08/21 Craig-Hallum
Westport target raised to $24 following Amazon truck order, says Craig-Hallum
CVAC CureVac
$100.40 /

+6.34 (+6.74%)

04/26/21 Credit Suisse
CureVac assumed with an Underperform at Credit Suisse
04/26/21 Guggenheim
CureVac initiated with a Buy at Guggenheim
01/07/21 Morgan Stanley
CureVac COVID-19 deal provides 'sentiment boost' for Bayer, says Morgan Stanley
12/10/20 Credit Suisse
CureVac downgraded to Underperform on rising valuation at Credit Suisse
SEAH Sports Entertainment Acquisition
$10.14 /

-0.08 (-0.78%)

GTT GTT Communications
$1.53 /

+0.04 (+2.68%)

10/16/20 Raymond James
GTT achieved 'solid' EBITDA multiple in infrastructure sale, says Raymond James
08/11/20 Craig-Hallum
Craig-Hallum suspends rating on GTT Communications after filing delay
08/11/20 Raymond James
GTT Communications downgraded at Raymond James on financial reporting miscue
08/11/20 Raymond James
GTT Communications downgraded to Underperform from Outperform at Raymond James
BGS B&G Foods
$29.36 /

-0.29 (-0.98%)

03/22/21
Fly Intel: Top five analyst downgrades
03/22/21 Piper Sandler
B&G Foods downgraded to Neutral from Overweight at Piper Sandler
03/03/21 RBC Capital
B&G Foods price target lowered to $29 from $32 at RBC Capital
01/19/21 Stephens
B&G Foods initiated with an Equal Weight at Stephens
SVXY ProShares Short VIX Short-Term Futures
$51.97 /

+1.44 (+2.85%)

NMRD Nemaura Medical
$8.55 /

-0.245 (-2.79%)

YALA Yalla
$20.44 /

+0.35 (+1.74%)

03/12/21 Oppenheimer
Yalla upgraded to Outperform from Perform at Oppenheimer
03/12/21 Oppenheimer
Yalla upgraded to Outperform from Perform at Oppenheimer
12/10/20 Oppenheimer
Yalla initiated with a Perform on valuation at Oppenheimer
12/10/20 Oppenheimer
Yalla initiated with a Perform at Oppenheimer
MNMD MindMed
$3.28 /

-0.11 (-3.24%)

EH Ehang
$23.42 /

+0.03 (+0.13%)

04/13/21
Fly Intel: Top five analyst downgrades
04/13/21 Morgan Stanley
Morgan Stanley cuts Ehang to Equal Weight on regulatory, competitive uncertainty
04/13/21 Morgan Stanley
Ehang downgraded to Equal Weight from Overweight at Morgan Stanley
WPRT Westport
$6.24 /

+0.105 (+1.71%)

NMRD Nemaura Medical
$8.55 /

-0.245 (-2.79%)

BGS B&G Foods
$29.36 /

-0.29 (-0.98%)

  • 28
    Jan
  • 30
    Sep
  • 14
    Aug
WPRT Westport
$6.24 /

+0.105 (+1.71%)

EH Ehang
$23.42 /

+0.03 (+0.13%)

CVAC CureVac
$100.40 /

+6.34 (+6.74%)

WPRT Westport
$6.24 /

+0.105 (+1.71%)

SEAH Sports Entertainment Acquisition
$10.14 /

-0.08 (-0.78%)

EH Ehang
$23.42 /

+0.03 (+0.13%)

CVAC CureVac
$100.40 /

+6.34 (+6.74%)

BGS B&G Foods
$29.36 /

-0.29 (-0.98%)

YALA Yalla
$20.44 /

+0.35 (+1.74%)

WPRT Westport
$6.24 /

+0.105 (+1.71%)

SEAH Sports Entertainment Acquisition
$10.14 /

-0.08 (-0.78%)

NMRD Nemaura Medical
$8.55 /

-0.245 (-2.79%)

MNMD MindMed
$3.28 /

-0.11 (-3.24%)

EH Ehang
$23.42 /

+0.03 (+0.13%)

CVAC CureVac
$100.40 /

+6.34 (+6.74%)

BGS B&G Foods
$29.36 /

-0.29 (-0.98%)

On The Fly
Moderna, Pfizer slip despite stronger results as U.S. backs vaccine IP waiver » 14:30
05/06/21
05/06
14:30
05/06/21
14:30
MRNA

Moderna

$160.79 /

-1.89 (-1.16%)

, PFE

Pfizer

$38.91 /

-0.67 (-1.69%)

, BNTX

BioNTech

$170.34 /

-0.34 (-0.20%)

, AZN

AstraZeneca

$53.14 /

-0.48 (-0.90%)

, JNJ

Johnson & Johnson

$166.93 /

-0.16 (-0.10%)

, NVAX

Novavax

$175.00 /

+3.02 (+1.76%)

, VXRT

Vaxart

$6.88 /

-0.485 (-6.59%)

, CVAC

CureVac

$93.63 /

-7.39 (-7.32%)

While both Moderna (MRNA)…

ShowHide Related Items >><<
VXRT Vaxart
$6.88 /

-0.485 (-6.59%)

PFE Pfizer
$38.91 /

-0.67 (-1.69%)

NVAX Novavax
$175.00 /

+3.02 (+1.76%)

MRNA Moderna
$160.79 /

-1.89 (-1.16%)

JNJ Johnson & Johnson
$166.93 /

-0.16 (-0.10%)

CVAC CureVac
$93.63 /

-7.39 (-7.32%)

BNTX BioNTech
$170.34 /

-0.34 (-0.20%)

AZN AstraZeneca
$53.14 /

-0.48 (-0.90%)

MRNA Moderna
$160.79 /

-1.89 (-1.16%)

05/05/21 Jefferies
Jefferies says COVID vaccine availability a supply-chain issue
05/03/21 Piper Sandler
Piper reiterates $234 target on Moderna after WHO Emergency Use Listing
04/29/21 Piper Sandler
Piper keeps $234 target on Moderna after raised Covid vaccine guidance
04/15/21 Piper Sandler
Moderna price target raised to $234 from $208 at Piper Sandler
PFE Pfizer
$38.91 /

-0.67 (-1.69%)

05/06/21
Fly Intel: Top five analyst downgrades
05/06/21 Mizuho
Pfizer downgraded to Neutral from Buy at Mizuho
05/05/21 JPMorgan
Pfizer price target raised to $40 from $36 at JPMorgan
05/05/21 Barclays
Pfizer price target raised to $40 from $37 at Barclays
BNTX BioNTech
$170.34 /

-0.34 (-0.20%)

02/23/21 B. Riley
B. Riley remains 'aggressive' buyer of Novavax after updated FDA guidance
02/01/21 SVB Leerink
Moderna price target raised to $80 from $69 at SVB Leerink
01/29/21 Piper Sandler
Moderna, Pfizer keep Covid vaccine competitive advantage, says Piper Sandler
01/14/21 Morgan Stanley
80%+ efficacy from J&J vaccine would be 'compelling,' says Morgan Stanley
AZN AstraZeneca
$53.14 /

-0.48 (-0.90%)

05/05/21 Oppenheimer
Alexion upgraded to Outperform from Perform at Oppenheimer
04/30/21 Wedbush
Alexion's Q1 report 'uneventful' after FTC grants deal clearance, says Wedbush
04/14/21 Guggenheim
Emergent BioSolutions price target lowered to $110 from $130 at Guggenheim
04/12/21
Fly Intel: Top five analyst downgrades
JNJ Johnson & Johnson
$166.93 /

-0.16 (-0.10%)

05/05/21 Argus
Emergent BioSolutions downgraded to Hold from Buy at Argus
04/29/21 Wells Fargo
Boston Scientific price target raised to $50 from $42 at Wells Fargo
04/26/21 B. Riley
B. Riley reiterates Buy on Novavax, Sell on Arcturus amid vaccine developments
04/19/21 Chardan
Chardan sees J&J moving forward with Emergent if observations are minor
NVAX Novavax
$175.00 /

+3.02 (+1.76%)

03/26/21 B. Riley
Novavax selloff on 'rumored' production delay overdone, says B. Riley
03/12/21 H.C. Wainwright
Novavax price target raised to $317 from $207 at H.C. Wainwright
VXRT Vaxart
$6.88 /

-0.485 (-6.59%)

03/04/21 B. Riley
Vaxart price target lowered to $13 from $16 at B. Riley Securities
11/18/20 B. Riley
Vaxart price target lowered to $16 from $22 at B. Riley Securities
10/13/20 B. Riley
B. Riley views Vaxart as key player in 'second wave' of Covid vaccines
09/09/20 B. Riley
Astra trial hold opens window for other vaccine candidates, says B. Riley FBR
CVAC CureVac
$93.63 /

-7.39 (-7.32%)

04/26/21 Credit Suisse
CureVac assumed with an Underperform at Credit Suisse
04/26/21 Guggenheim
CureVac initiated with a Buy at Guggenheim
01/07/21 Morgan Stanley
CureVac COVID-19 deal provides 'sentiment boost' for Bayer, says Morgan Stanley
12/10/20 Credit Suisse
CureVac downgraded to Underperform on rising valuation at Credit Suisse
VXRT Vaxart
$6.88 /

-0.485 (-6.59%)

PFE Pfizer
$38.91 /

-0.67 (-1.69%)

NVAX Novavax
$175.00 /

+3.02 (+1.76%)

MRNA Moderna
$160.79 /

-1.89 (-1.16%)

JNJ Johnson & Johnson
$166.93 /

-0.16 (-0.10%)

AZN AstraZeneca
$53.14 /

-0.48 (-0.90%)

  • 28
    Jan
  • 14
    Aug
  • 23
    Jul
  • 19
    May
MRNA Moderna
$160.79 /

-1.89 (-1.16%)

JNJ Johnson & Johnson
$166.93 /

-0.16 (-0.10%)

CVAC CureVac
$93.63 /

-7.39 (-7.32%)

AZN AstraZeneca
$53.14 /

-0.48 (-0.90%)

VXRT Vaxart
$6.88 /

-0.485 (-6.59%)

PFE Pfizer
$38.91 /

-0.67 (-1.69%)

NVAX Novavax
$175.00 /

+3.02 (+1.76%)

MRNA Moderna
$160.79 /

-1.89 (-1.16%)

JNJ Johnson & Johnson
$166.93 /

-0.16 (-0.10%)

CVAC CureVac
$93.63 /

-7.39 (-7.32%)

BNTX BioNTech
$170.34 /

-0.34 (-0.20%)

AZN AstraZeneca
$53.14 /

-0.48 (-0.90%)

VXRT Vaxart
$6.88 /

-0.485 (-6.59%)

PFE Pfizer
$38.91 /

-0.67 (-1.69%)

NVAX Novavax
$175.00 /

+3.02 (+1.76%)

MRNA Moderna
$160.79 /

-1.89 (-1.16%)

JNJ Johnson & Johnson
$166.93 /

-0.16 (-0.10%)

CVAC CureVac
$93.63 /

-7.39 (-7.32%)

BNTX BioNTech
$170.34 /

-0.34 (-0.20%)

AZN AstraZeneca
$53.14 /

-0.48 (-0.90%)

Periodicals
Germany's Merkel opposed to vaccine patent waivers, Bloomberg reports » 12:14
05/06/21
05/06
12:14
05/06/21
12:14
MRNA

Moderna

$156.69 /

-5.99 (-3.68%)

, PFE

Pfizer

$38.89 /

-0.69 (-1.74%)

, BNTX

BioNTech

$164.18 /

-6.5 (-3.81%)

, AZN

AstraZeneca

$53.16 /

-0.46 (-0.86%)

, JNJ

Johnson & Johnson

$166.87 /

-0.22 (-0.13%)

, NVAX

Novavax

$168.55 /

-3.43 (-1.99%)

, CVAC

CureVac

$93.30 /

-7.72 (-7.64%)

, VXRT

Vaxart

$6.60 /

-0.765 (-10.39%)

German Chancellor Angela…

German Chancellor Angela Merkel is opposed to a U.S. proposal to waive patent protections for COVID-19 vaccines, stating that such a plan would create "severe complications" for the production of vaccines, reported Bloomberg, citing a German government spokeswoman. Without a profit incentive, drugmakers might not move as aggressively to make vaccines, the industry has argued. Companies with approved COVID-19 vaccines or working on such vaccines include Pfizer (PFE), BioNTech (BNTX), Moderna (MRNA), AstraZeneca (AZN), Johnson & Johnson (JNJ), Novavax (NVAX), Vaxart (VXRT) and CureVac (CVAC). Reference Link

ShowHide Related Items >><<
VXRT Vaxart
$6.60 /

-0.765 (-10.39%)

PFE Pfizer
$38.89 /

-0.69 (-1.74%)

NVAX Novavax
$168.55 /

-3.43 (-1.99%)

MRNA Moderna
$156.69 /

-5.99 (-3.68%)

JNJ Johnson & Johnson
$166.87 /

-0.22 (-0.13%)

CVAC CureVac
$93.30 /

-7.72 (-7.64%)

BNTX BioNTech
$164.18 /

-6.5 (-3.81%)

AZN AstraZeneca
$53.16 /

-0.46 (-0.86%)

MRNA Moderna
$156.69 /

-5.99 (-3.68%)

05/05/21 Jefferies
Jefferies says COVID vaccine availability a supply-chain issue
05/03/21 Piper Sandler
Piper reiterates $234 target on Moderna after WHO Emergency Use Listing
04/29/21 Piper Sandler
Piper keeps $234 target on Moderna after raised Covid vaccine guidance
04/15/21 Piper Sandler
Moderna price target raised to $234 from $208 at Piper Sandler
PFE Pfizer
$38.89 /

-0.69 (-1.74%)

05/06/21
Fly Intel: Top five analyst downgrades
05/06/21 Mizuho
Pfizer downgraded to Neutral from Buy at Mizuho
05/05/21 JPMorgan
Pfizer price target raised to $40 from $36 at JPMorgan
05/05/21 Barclays
Pfizer price target raised to $40 from $37 at Barclays
BNTX BioNTech
$164.18 /

-6.5 (-3.81%)

02/23/21 B. Riley
B. Riley remains 'aggressive' buyer of Novavax after updated FDA guidance
02/01/21 SVB Leerink
Moderna price target raised to $80 from $69 at SVB Leerink
01/29/21 Piper Sandler
Moderna, Pfizer keep Covid vaccine competitive advantage, says Piper Sandler
01/14/21 Morgan Stanley
80%+ efficacy from J&J vaccine would be 'compelling,' says Morgan Stanley
AZN AstraZeneca
$53.16 /

-0.46 (-0.86%)

05/05/21 Oppenheimer
Alexion upgraded to Outperform from Perform at Oppenheimer
04/30/21 Wedbush
Alexion's Q1 report 'uneventful' after FTC grants deal clearance, says Wedbush
04/14/21 Guggenheim
Emergent BioSolutions price target lowered to $110 from $130 at Guggenheim
04/12/21
Fly Intel: Top five analyst downgrades
JNJ Johnson & Johnson
$166.87 /

-0.22 (-0.13%)

05/05/21 Argus
Emergent BioSolutions downgraded to Hold from Buy at Argus
04/29/21 Wells Fargo
Boston Scientific price target raised to $50 from $42 at Wells Fargo
04/26/21 B. Riley
B. Riley reiterates Buy on Novavax, Sell on Arcturus amid vaccine developments
04/19/21 Chardan
Chardan sees J&J moving forward with Emergent if observations are minor
NVAX Novavax
$168.55 /

-3.43 (-1.99%)

03/26/21 B. Riley
Novavax selloff on 'rumored' production delay overdone, says B. Riley
03/12/21 H.C. Wainwright
Novavax price target raised to $317 from $207 at H.C. Wainwright
CVAC CureVac
$93.30 /

-7.72 (-7.64%)

04/26/21 Credit Suisse
CureVac assumed with an Underperform at Credit Suisse
04/26/21 Guggenheim
CureVac initiated with a Buy at Guggenheim
01/07/21 Morgan Stanley
CureVac COVID-19 deal provides 'sentiment boost' for Bayer, says Morgan Stanley
12/10/20 Credit Suisse
CureVac downgraded to Underperform on rising valuation at Credit Suisse
VXRT Vaxart
$6.60 /

-0.765 (-10.39%)

03/04/21 B. Riley
Vaxart price target lowered to $13 from $16 at B. Riley Securities
11/18/20 B. Riley
Vaxart price target lowered to $16 from $22 at B. Riley Securities
10/13/20 B. Riley
B. Riley views Vaxart as key player in 'second wave' of Covid vaccines
09/09/20 B. Riley
Astra trial hold opens window for other vaccine candidates, says B. Riley FBR
VXRT Vaxart
$6.60 /

-0.765 (-10.39%)

PFE Pfizer
$38.89 /

-0.69 (-1.74%)

NVAX Novavax
$168.55 /

-3.43 (-1.99%)

MRNA Moderna
$156.69 /

-5.99 (-3.68%)

JNJ Johnson & Johnson
$166.87 /

-0.22 (-0.13%)

AZN AstraZeneca
$53.16 /

-0.46 (-0.86%)

  • 28
    Jan
  • 14
    Aug
  • 23
    Jul
  • 19
    May
PFE Pfizer
$38.89 /

-0.69 (-1.74%)

NVAX Novavax
$168.55 /

-3.43 (-1.99%)

MRNA Moderna
$156.69 /

-5.99 (-3.68%)

JNJ Johnson & Johnson
$166.87 /

-0.22 (-0.13%)

CVAC CureVac
$93.30 /

-7.72 (-7.64%)

AZN AstraZeneca
$53.16 /

-0.46 (-0.86%)

VXRT Vaxart
$6.60 /

-0.765 (-10.39%)

PFE Pfizer
$38.89 /

-0.69 (-1.74%)

NVAX Novavax
$168.55 /

-3.43 (-1.99%)

MRNA Moderna
$156.69 /

-5.99 (-3.68%)

JNJ Johnson & Johnson
$166.87 /

-0.22 (-0.13%)

CVAC CureVac
$93.30 /

-7.72 (-7.64%)

BNTX BioNTech
$164.18 /

-6.5 (-3.81%)

AZN AstraZeneca
$53.16 /

-0.46 (-0.86%)

VXRT Vaxart
$6.60 /

-0.765 (-10.39%)

PFE Pfizer
$38.89 /

-0.69 (-1.74%)

NVAX Novavax
$168.55 /

-3.43 (-1.99%)

MRNA Moderna
$156.69 /

-5.99 (-3.68%)

JNJ Johnson & Johnson
$166.87 /

-0.22 (-0.13%)

CVAC CureVac
$93.30 /

-7.72 (-7.64%)

BNTX BioNTech
$164.18 /

-6.5 (-3.81%)

AZN AstraZeneca
$53.16 /

-0.46 (-0.86%)

Periodicals
Merkel opposes plan to waive COVID vaccine patent protection, Bloomberg says » 11:25
05/06/21
05/06
11:25
05/06/21
11:25
MRNA

Moderna

$148.75 /

-13.93 (-8.56%)

, PFE

Pfizer

$38.52 /

-1.06 (-2.68%)

, BNTX

BioNTech

$159.00 /

-11.68 (-6.84%)

, AZN

AstraZeneca

$53.02 /

-0.6 (-1.12%)

, JNJ

Johnson & Johnson

$166.44 /

-0.65 (-0.39%)

, NVAX

Novavax

$163.78 /

-8.2 (-4.77%)

, CVAC

CureVac

$90.08 /

-10.94 (-10.83%)

, VXRT

Vaxart

$6.41 /

-0.955 (-12.97%)

Bloomberg cites a German…

Bloomberg cites a German government spokesperson as saying that the U.S. plan would create "severe complications" for the production of vaccines. Companies with approved COVID-19 vaccines or working on such vaccines include Pfizer (PFE), BioNTech (BNTX), Moderna (MRNA), AstraZeneca (AZN), Johnson & Johnson (JNJ), Novavax (NVAX), Vaxart (VXRT) and CureVac (CVAC).

ShowHide Related Items >><<
VXRT Vaxart
$6.41 /

-0.955 (-12.97%)

PFE Pfizer
$38.52 /

-1.06 (-2.68%)

NVAX Novavax
$163.78 /

-8.2 (-4.77%)

MRNA Moderna
$148.75 /

-13.93 (-8.56%)

JNJ Johnson & Johnson
$166.44 /

-0.65 (-0.39%)

CVAC CureVac
$90.08 /

-10.94 (-10.83%)

BNTX BioNTech
$159.00 /

-11.68 (-6.84%)

AZN AstraZeneca
$53.02 /

-0.6 (-1.12%)

MRNA Moderna
$148.75 /

-13.93 (-8.56%)

05/05/21 Jefferies
Jefferies says COVID vaccine availability a supply-chain issue
05/03/21 Piper Sandler
Piper reiterates $234 target on Moderna after WHO Emergency Use Listing
04/29/21 Piper Sandler
Piper keeps $234 target on Moderna after raised Covid vaccine guidance
04/15/21 Piper Sandler
Moderna price target raised to $234 from $208 at Piper Sandler
PFE Pfizer
$38.52 /

-1.06 (-2.68%)

05/06/21
Fly Intel: Top five analyst downgrades
05/06/21 Mizuho
Pfizer downgraded to Neutral from Buy at Mizuho
05/05/21 JPMorgan
Pfizer price target raised to $40 from $36 at JPMorgan
05/05/21 Barclays
Pfizer price target raised to $40 from $37 at Barclays
BNTX BioNTech
$159.00 /

-11.68 (-6.84%)

02/23/21 B. Riley
B. Riley remains 'aggressive' buyer of Novavax after updated FDA guidance
02/01/21 SVB Leerink
Moderna price target raised to $80 from $69 at SVB Leerink
01/29/21 Piper Sandler
Moderna, Pfizer keep Covid vaccine competitive advantage, says Piper Sandler
01/14/21 Morgan Stanley
80%+ efficacy from J&J vaccine would be 'compelling,' says Morgan Stanley
AZN AstraZeneca
$53.02 /

-0.6 (-1.12%)

05/05/21 Oppenheimer
Alexion upgraded to Outperform from Perform at Oppenheimer
04/30/21 Wedbush
Alexion's Q1 report 'uneventful' after FTC grants deal clearance, says Wedbush
04/14/21 Guggenheim
Emergent BioSolutions price target lowered to $110 from $130 at Guggenheim
04/12/21
Fly Intel: Top five analyst downgrades
JNJ Johnson & Johnson
$166.44 /

-0.65 (-0.39%)

05/05/21 Argus
Emergent BioSolutions downgraded to Hold from Buy at Argus
04/29/21 Wells Fargo
Boston Scientific price target raised to $50 from $42 at Wells Fargo
04/26/21 B. Riley
B. Riley reiterates Buy on Novavax, Sell on Arcturus amid vaccine developments
04/19/21 Chardan
Chardan sees J&J moving forward with Emergent if observations are minor
NVAX Novavax
$163.78 /

-8.2 (-4.77%)

03/26/21 B. Riley
Novavax selloff on 'rumored' production delay overdone, says B. Riley
03/12/21 H.C. Wainwright
Novavax price target raised to $317 from $207 at H.C. Wainwright
CVAC CureVac
$90.08 /

-10.94 (-10.83%)

04/26/21 Credit Suisse
CureVac assumed with an Underperform at Credit Suisse
04/26/21 Guggenheim
CureVac initiated with a Buy at Guggenheim
01/07/21 Morgan Stanley
CureVac COVID-19 deal provides 'sentiment boost' for Bayer, says Morgan Stanley
12/10/20 Credit Suisse
CureVac downgraded to Underperform on rising valuation at Credit Suisse
VXRT Vaxart
$6.41 /

-0.955 (-12.97%)

03/04/21 B. Riley
Vaxart price target lowered to $13 from $16 at B. Riley Securities
11/18/20 B. Riley
Vaxart price target lowered to $16 from $22 at B. Riley Securities
10/13/20 B. Riley
B. Riley views Vaxart as key player in 'second wave' of Covid vaccines
09/09/20 B. Riley
Astra trial hold opens window for other vaccine candidates, says B. Riley FBR
VXRT Vaxart
$6.41 /

-0.955 (-12.97%)

PFE Pfizer
$38.52 /

-1.06 (-2.68%)

NVAX Novavax
$163.78 /

-8.2 (-4.77%)

MRNA Moderna
$148.75 /

-13.93 (-8.56%)

JNJ Johnson & Johnson
$166.44 /

-0.65 (-0.39%)

AZN AstraZeneca
$53.02 /

-0.6 (-1.12%)

  • 28
    Jan
  • 14
    Aug
  • 23
    Jul
  • 19
    May
PFE Pfizer
$38.52 /

-1.06 (-2.68%)

NVAX Novavax
$163.78 /

-8.2 (-4.77%)

MRNA Moderna
$148.75 /

-13.93 (-8.56%)

JNJ Johnson & Johnson
$166.44 /

-0.65 (-0.39%)

CVAC CureVac
$90.08 /

-10.94 (-10.83%)

AZN AstraZeneca
$53.02 /

-0.6 (-1.12%)

VXRT Vaxart
$6.41 /

-0.955 (-12.97%)

PFE Pfizer
$38.52 /

-1.06 (-2.68%)

NVAX Novavax
$163.78 /

-8.2 (-4.77%)

MRNA Moderna
$148.75 /

-13.93 (-8.56%)

JNJ Johnson & Johnson
$166.44 /

-0.65 (-0.39%)

CVAC CureVac
$90.08 /

-10.94 (-10.83%)

BNTX BioNTech
$159.00 /

-11.68 (-6.84%)

AZN AstraZeneca
$53.02 /

-0.6 (-1.12%)

VXRT Vaxart
$6.41 /

-0.955 (-12.97%)

PFE Pfizer
$38.52 /

-1.06 (-2.68%)

NVAX Novavax
$163.78 /

-8.2 (-4.77%)

MRNA Moderna
$148.75 /

-13.93 (-8.56%)

JNJ Johnson & Johnson
$166.44 /

-0.65 (-0.39%)

CVAC CureVac
$90.08 /

-10.94 (-10.83%)

BNTX BioNTech
$159.00 /

-11.68 (-6.84%)

AZN AstraZeneca
$53.02 /

-0.6 (-1.12%)

Options
Largest borrow rate increases among liquid names » 08:45
05/06/21
05/06
08:45
05/06/21
08:45
IRBT

iRobot

$95.31 /

-0.72 (-0.75%)

, WPRT

Westport

$6.44 /

-0.09 (-1.38%)

, DUST

Direxion Daily Gold Miners Bear 3X ETF

$18.15 /

-0.325 (-1.76%)

, ACB

Aurora Cannabis

$8.78 /

+0.11 (+1.27%)

, FTAI

Fortress Transportation

$27.54 /

+0.19 (+0.69%)

, WRAP

Wrap Technologies

$6.15 /

+0.11 (+1.82%)

, CVAC

CureVac

$101.00 /

-8.31 (-7.60%)

, FSR

Fisker

$11.38 /

-0.6 (-5.01%)

, WKHS

Workhorse Group

$10.98 /

-0.21 (-1.88%)

Latest data shows the…

Latest data shows the largest indicative borrow rate increases among liquid option names include: iRobot (IRBT) 43.50% +43.10, Westport (WPRT) 6.33% +2.59, Gold Bear 3x (DUST) 13.24% +1.57, Aurora Cannabis (ACB) 69.47% +1.19, Fortress Transportation (FTAI) 1.45% +0.79, Wrap Technologies (WRAP) 23.44% +0.56, Global X Uranium (URA) 2.74% +0.55, CureVac (CVAC) 11.96% +0.48, Fisker (FSR) 3.99% +0.43, and Workhorse Group (WKHS) 5.75% +0.40.

ShowHide Related Items >><<
WRAP Wrap Technologies
$6.15 /

+0.11 (+1.82%)

WPRT Westport
$6.44 /

-0.09 (-1.38%)

WKHS Workhorse Group
$10.98 /

-0.21 (-1.88%)

IRBT iRobot
$95.31 /

-0.72 (-0.75%)

FTAI Fortress Transportation
$27.54 /

+0.19 (+0.69%)

FSR Fisker
$11.38 /

-0.6 (-5.01%)

DUST Direxion Daily Gold Miners Bear 3X ETF
$18.15 /

-0.325 (-1.76%)

CVAC CureVac
$101.00 /

-8.31 (-7.60%)

ACB Aurora Cannabis
$8.78 /

+0.11 (+1.27%)

IRBT iRobot
$95.31 /

-0.72 (-0.75%)

02/12/21 Northland
iRobot price target raised to $140 from $120 at Northland
02/12/21 Citi
iRobot price target raised to $140 from $95 at Citi
02/11/21 JPMorgan
iRobot upgraded to Overweight from Neutral at JPMorgan
02/11/21 JPMorgan
iRobot upgraded to Overweight from Neutral at JPMorgan
WPRT Westport
$6.44 /

-0.09 (-1.38%)

03/18/21 Lake Street
Lake Street confidence in Westport's China ramp boosted by Weichai deal
03/17/21 H.C. Wainwright
Westport price target raised to $16 from $5 at H.C. Wainwright
02/08/21 Craig-Hallum
Clean Energy price target raised to $25 from $12 at Craig-Hallum
02/08/21 Craig-Hallum
Westport target raised to $24 following Amazon truck order, says Craig-Hallum
DUST Direxion Daily Gold Miners Bear 3X ETF
$18.15 /

-0.325 (-1.76%)

ACB Aurora Cannabis
$8.78 /

+0.11 (+1.27%)

04/28/21 BofA
Aurora Cannabis reinstated with a Neutral at BofA
04/28/21 BofA
Tilray reinstated with a Buy at BofA
04/05/21 CIBC
Aurora Cannabis price target lowered to C$15 from C$18.50 at CIBC
03/29/21 Stifel
Stifel says New York adult use cannabis market represents $5B opportunity
FTAI Fortress Transportation
$27.54 /

+0.19 (+0.69%)

03/05/21 B. Riley
Fortress Transportation price target raised to $37 from $31 at B. Riley
03/01/21 Barclays
Fortress Transportation price target raised to $30 from $23 at Barclays
02/23/21 JMP Securities
Fortress Transportation price target raised to $32 from $22 at JMP Securities
02/22/21 B. Riley
Fortress Transportation price target raised to $31 from $27 at B. Riley
WRAP Wrap Technologies
$6.15 /

+0.11 (+1.82%)

04/15/21 Maxim
Wrap Technologies initiated with a Buy at Maxim
04/15/21 Maxim
Wrap Technologies initiated with a Buy at Maxim
CVAC CureVac
$101.00 /

-8.31 (-7.60%)

04/26/21 Credit Suisse
CureVac assumed with an Underperform at Credit Suisse
04/26/21 Guggenheim
CureVac initiated with a Buy at Guggenheim
01/07/21 Morgan Stanley
CureVac COVID-19 deal provides 'sentiment boost' for Bayer, says Morgan Stanley
12/10/20 Credit Suisse
CureVac downgraded to Underperform on rising valuation at Credit Suisse
FSR Fisker
$11.38 /

-0.6 (-5.01%)

04/22/21
Fly Intel: Top five analyst downgrades
04/22/21 Goldman Sachs
Fisker downgraded to Sell from Neutral at Goldman Sachs
04/20/21 Morgan Stanley
Fisker remains 'top ranked' EV related SPAC startup, says Morgan Stanley
04/20/21 BofA
Fisker initiated with a Buy at BofA
WKHS Workhorse Group
$10.98 /

-0.21 (-1.88%)

04/16/21 B. Riley
B. Riley says Workhorse can deliver without Post Office, starts with Buy
04/15/21 B. Riley
Workhorse Group initiated with a Buy at B. Riley
02/24/21
Fly Intel: Top five analyst downgrades
02/24/21 Oppenheimer
Opco downgrades Workhorse after Postal Service snub despite backlog
WRAP Wrap Technologies
$6.15 /

+0.11 (+1.82%)

WPRT Westport
$6.44 /

-0.09 (-1.38%)

WKHS Workhorse Group
$10.98 /

-0.21 (-1.88%)

IRBT iRobot
$95.31 /

-0.72 (-0.75%)

FTAI Fortress Transportation
$27.54 /

+0.19 (+0.69%)

FSR Fisker
$11.38 /

-0.6 (-5.01%)

ACB Aurora Cannabis
$8.78 /

+0.11 (+1.27%)

  • 28
    Jan
  • 22
    Jan
  • 11
    Nov
  • 14
    Aug
WPRT Westport
$6.44 /

-0.09 (-1.38%)

WKHS Workhorse Group
$10.98 /

-0.21 (-1.88%)

FSR Fisker
$11.38 /

-0.6 (-5.01%)

CVAC CureVac
$101.00 /

-8.31 (-7.60%)

ACB Aurora Cannabis
$8.78 /

+0.11 (+1.27%)

WPRT Westport
$6.44 /

-0.09 (-1.38%)

WKHS Workhorse Group
$10.98 /

-0.21 (-1.88%)

IRBT iRobot
$95.31 /

-0.72 (-0.75%)

FSR Fisker
$11.38 /

-0.6 (-5.01%)

CVAC CureVac
$101.00 /

-8.31 (-7.60%)

ACB Aurora Cannabis
$8.78 /

+0.11 (+1.27%)

WRAP Wrap Technologies
$6.15 /

+0.11 (+1.82%)

WPRT Westport
$6.44 /

-0.09 (-1.38%)

WKHS Workhorse Group
$10.98 /

-0.21 (-1.88%)

IRBT iRobot
$95.31 /

-0.72 (-0.75%)

FTAI Fortress Transportation
$27.54 /

+0.19 (+0.69%)

FSR Fisker
$11.38 /

-0.6 (-5.01%)

DUST Direxion Daily Gold Miners Bear 3X ETF
$18.15 /

-0.325 (-1.76%)

CVAC CureVac
$101.00 /

-8.31 (-7.60%)

ACB Aurora Cannabis
$8.78 /

+0.11 (+1.27%)

Options
Largest borrow rate increases among liquid names » 08:45
04/26/21
04/26
08:45
04/26/21
08:45
GOEV

Canoo

$8.70 /

+0.255 (+3.02%)

, ENIA

Enel Americas

$7.55 /

-0.04 (-0.53%)

, ACB

Aurora Cannabis

$8.37 /

+0.37 (+4.63%)

, CVAC

CureVac

$116.28 /

+2.32 (+2.04%)

, WISH

ContextLogic

$13.54 /

+0.45 (+3.44%)

, HUGE

FSD Pharma

$1.65 /

+0.045 (+2.80%)

, BTBT

Bit Digital

$13.26 /

+0.41 (+3.19%)

, CS

Credit Suisse

$10.45 /

+0.43 (+4.29%)

, STPK

Star Peak Energy Transition

$25.79 /

+1.96 (+8.22%)

, DNN

Denison Mines

$1.00 /

-0.0044 (-0.44%)

Latest data shows the…

Latest data shows the largest indicative borrow rate increases among liquid option names include: Canoo (GOEV) 35.93% +9.69, Enersis Americas (ENIA) 6.64% +4.68, Aurora Cannabis (ACB) 71.68% +1.87, CureVac (CVAC) 13.87% +0.77, ContextLogic (WISH) 7.60% +0.66, FDS Pharma (HUGE) 19.51% +0.64, Bit Digital (BTBT) 82.96% +0.57, Credit Suisse (CS) 3.93% +0.50, Star Peak Energy Transition (STPK) 6.30% +0.37, and Denison Mines (DNN) 2.32% +0.22.

ShowHide Related Items >><<
WISH ContextLogic
$13.54 /

+0.45 (+3.44%)

STPK Star Peak Energy Transition
$25.79 /

+1.96 (+8.22%)

HUGE FSD Pharma
$1.65 /

+0.045 (+2.80%)

GOEV Canoo
$8.70 /

+0.255 (+3.02%)

ENIA Enel Americas
$7.55 /

-0.04 (-0.53%)

DNN Denison Mines
$1.00 /

-0.0044 (-0.44%)

CVAC CureVac
$116.28 /

+2.32 (+2.04%)

CS Credit Suisse
$10.45 /

+0.43 (+4.29%)

BTBT Bit Digital
$13.26 /

+0.41 (+3.19%)

ACB Aurora Cannabis
$8.37 /

+0.37 (+4.63%)

GOEV Canoo
$8.70 /

+0.255 (+3.02%)

04/20/21 BofA
Canoo initiated with an Underperform at BofA
04/20/21 BofA
Canoo initiated with an Underperform at BofA
03/30/21 Roth Capital
Canoo downgraded to Neutral at Roth Capital on 'complete change in direction'
03/30/21 Roth Capital
Canoo downgraded to Neutral from Buy at Roth Capital
ENIA Enel Americas
$7.55 /

-0.04 (-0.53%)

ACB Aurora Cannabis
$8.37 /

+0.37 (+4.63%)

04/05/21 CIBC
Aurora Cannabis price target lowered to C$15 from C$18.50 at CIBC
03/29/21 Stifel
Stifel says New York adult use cannabis market represents $5B opportunity
02/16/21 CIBC
Aurora Cannabis price target raised to C$18.50 from C$17 at CIBC
02/16/21 GLJ Research
Aurora Cannabis shares have 100% downside by end of 2022, says GLJ Research
CVAC CureVac
$116.28 /

+2.32 (+2.04%)

04/26/21 Credit Suisse
CureVac assumed with an Underperform at Credit Suisse
04/26/21 Guggenheim
CureVac initiated with a Buy at Guggenheim
01/07/21 Morgan Stanley
CureVac COVID-19 deal provides 'sentiment boost' for Bayer, says Morgan Stanley
12/10/20 Credit Suisse
CureVac downgraded to Underperform on rising valuation at Credit Suisse
WISH ContextLogic
$13.54 /

+0.45 (+3.44%)

04/05/21 Evercore ISI
ContextLogic initiated with an Outperform at Evercore ISI
03/30/21 Loop Capital
ContextLogic to 'lap' easy comparisons in Q1, says Loop Capital
03/18/21 JPMorgan
ContextLogic shares attractive at current levels, says JPMorgan
03/09/21 Stifel
ContextLogic price target lowered to $20 from $22 at Stifel
HUGE FSD Pharma
$1.65 /

+0.045 (+2.80%)

08/20/20 Brookline
FSD Pharma initiated with a Buy at Brookline
BTBT Bit Digital
$13.26 /

+0.41 (+3.19%)

CS Credit Suisse
$10.45 /

+0.43 (+4.29%)

04/23/21 Societe Generale
Credit Suisse price target lowered to CHF 10 from CHF 11 at Societe Generale
04/21/21 Barclays
Credit Suisse price target lowered to CHF 12 from CHF 14 at Barclays
04/15/21 Deutsche Bank
Credit Suisse price target lowered to CHF 12 from CHF 15 at Deutsche Bank
04/12/21 UBS
Credit Suisse price target lowered to CHF 10.20 from CHF 12.10 at UBS
STPK Star Peak Energy Transition
$25.79 /

+1.96 (+8.22%)

DNN Denison Mines
$1.00 /

-0.0044 (-0.44%)

03/24/21 Raymond James
Denison Mines price target raised to C$1.70 from C$1.20 at Raymond James
02/25/21 TD Securities
Denison Mines price target raised to C$1.55 from C$1 at TD Securities
02/10/21 Raymond James
Denison Mines price target raised to C$1.20 from C$1.15 at Raymond James
01/21/21 Canaccord
Denison Mines price target raised to C$1.10 from C$0.90 at Canaccord
WISH ContextLogic
$13.54 /

+0.45 (+3.44%)

GOEV Canoo
$8.70 /

+0.255 (+3.02%)

CS Credit Suisse
$10.45 /

+0.43 (+4.29%)

ACB Aurora Cannabis
$8.37 /

+0.37 (+4.63%)

  • 28
    Jan
  • 22
    Jan
  • 16
    Dec
  • 11
    Nov
  • 14
    Aug
WISH ContextLogic
$13.54 /

+0.45 (+3.44%)

STPK Star Peak Energy Transition
$25.79 /

+1.96 (+8.22%)

GOEV Canoo
$8.70 /

+0.255 (+3.02%)

CVAC CureVac
$116.28 /

+2.32 (+2.04%)

CS Credit Suisse
$10.45 /

+0.43 (+4.29%)

BTBT Bit Digital
$13.26 /

+0.41 (+3.19%)

ACB Aurora Cannabis
$8.37 /

+0.37 (+4.63%)

WISH ContextLogic
$13.54 /

+0.45 (+3.44%)

GOEV Canoo
$8.70 /

+0.255 (+3.02%)

CVAC CureVac
$116.28 /

+2.32 (+2.04%)

CS Credit Suisse
$10.45 /

+0.43 (+4.29%)

BTBT Bit Digital
$13.26 /

+0.41 (+3.19%)

ACB Aurora Cannabis
$8.37 /

+0.37 (+4.63%)

WISH ContextLogic
$13.54 /

+0.45 (+3.44%)

STPK Star Peak Energy Transition
$25.79 /

+1.96 (+8.22%)

HUGE FSD Pharma
$1.65 /

+0.045 (+2.80%)

GOEV Canoo
$8.70 /

+0.255 (+3.02%)

DNN Denison Mines
$1.00 /

-0.0044 (-0.44%)

CVAC CureVac
$116.28 /

+2.32 (+2.04%)

CS Credit Suisse
$10.45 /

+0.43 (+4.29%)

BTBT Bit Digital
$13.26 /

+0.41 (+3.19%)

ACB Aurora Cannabis
$8.37 /

+0.37 (+4.63%)

Initiation
CureVac assumed with an Underperform at Credit Suisse » 06:56
04/26/21
04/26
06:56
04/26/21
06:56
CVAC

CureVac

$116.28 /

+2.32 (+2.04%)

Credit Suisse analyst…

Credit Suisse analyst Tiago Fauth assumed coverage of CureVac with an unchanged Underperform rating and $50 price target.

ShowHide Related Items >><<
CVAC CureVac
$116.28 /

+2.32 (+2.04%)

CVAC CureVac
$116.28 /

+2.32 (+2.04%)

04/26/21 Guggenheim
CureVac initiated with a Buy at Guggenheim
01/07/21 Morgan Stanley
CureVac COVID-19 deal provides 'sentiment boost' for Bayer, says Morgan Stanley
12/10/20 Credit Suisse
CureVac downgraded to Underperform on rising valuation at Credit Suisse
12/10/20 Credit Suisse
CureVac downgraded to Underperform from Neutral at Credit Suisse
  • 28
    Jan
  • 14
    Aug
CVAC CureVac
$116.28 /

+2.32 (+2.04%)

CVAC CureVac
$116.28 /

+2.32 (+2.04%)

CVAC CureVac
$116.28 /

+2.32 (+2.04%)

Initiation
CureVac initiated with a Buy at Guggenheim » 06:25
04/26/21
04/26
06:25
04/26/21
06:25
CVAC

CureVac

$116.28 /

+2.32 (+2.04%)

Guggenheim initiated…

Guggenheim initiated coverage of CureVac with a Buy rating.

ShowHide Related Items >><<
CVAC CureVac
$116.28 /

+2.32 (+2.04%)

CVAC CureVac
$116.28 /

+2.32 (+2.04%)

01/07/21 Morgan Stanley
CureVac COVID-19 deal provides 'sentiment boost' for Bayer, says Morgan Stanley
12/10/20 Credit Suisse
CureVac downgraded to Underperform on rising valuation at Credit Suisse
12/10/20 Credit Suisse
CureVac downgraded to Underperform from Neutral at Credit Suisse
11/02/20 Piper Sandler
CureVac's positive vaccine data bodes well for Arcturus's ARCT-021, says Piper
  • 28
    Jan
  • 14
    Aug
CVAC CureVac
$116.28 /

+2.32 (+2.04%)

CVAC CureVac
$116.28 /

+2.32 (+2.04%)

CVAC CureVac
$116.28 /

+2.32 (+2.04%)

Over a month ago
Hot Stocks
CureVac provides business update, Covid-19 progress » 07:54
04/15/21
04/15
07:54
04/15/21
07:54
CVAC

CureVac

$102.60 /

+6.61 (+6.89%)

"2020 was a year of…

"2020 was a year of fundamental corporate transformation, which has propelled CureVac forward in its growth from a research-oriented biotech to an integrated, commercial biopharma company based on our unique mRNA technology and a broad clinical COVID-19 vaccine program," said Franz-Werner Haas, Chief Executive Officer of CureVac. "mRNA has emerged as a key technology that leads the charge against the COVID-19 pandemic, but it is only starting to realize its full potential in the development of new prophylactic vaccines and therapeutics in other areas such as oncology. Moving into 2021, we will continue the development of our company and, subject to regulatory approval, execute on our core mandate to broadly deliver a safe and effective COVID-19 vaccine. We have made great progress in achieving these goals and are now leveraging the solid foundation we laid to further tackle emerging variants in our COVID-19 vaccine program, advance into second-generation COVID-19 vaccines and infectious diseases and expand our clinical pipeline in oncology and protein therapies." "We closed 2020 with a strong cash position of EUR 1.32 billion, including the proceeds of a private round financing in July, our IPO in August and a grant from the German government in September. This was further complemented by a significant upfront payment from our Advanced Purchase Agreement with the European Commission for 225 million doses of CVnCoV with an option for an additional 180 million doses," said Pierre Kemula, Chief Financial Officer of CureVac. "In addition, in February 2021, we successfully raised aggregated gross proceeds of approximately $517.5 million in our first follow-on financing. With our strong cash position, we believe we are in a great position to accelerate our corporate transformation from a research-oriented biotech to a commercial-stage biopharma company and to continue to grow the business around our broad clinical pipeline while building up commercial expertise and infrastructure."

ShowHide Related Items >><<
CVAC CureVac
$102.60 /

+6.61 (+6.89%)

CVAC CureVac
$102.60 /

+6.61 (+6.89%)

01/07/21 Morgan Stanley
CureVac COVID-19 deal provides 'sentiment boost' for Bayer, says Morgan Stanley
12/10/20 Credit Suisse
CureVac downgraded to Underperform on rising valuation at Credit Suisse
12/10/20 Credit Suisse
CureVac downgraded to Underperform from Neutral at Credit Suisse
11/02/20 Piper Sandler
CureVac's positive vaccine data bodes well for Arcturus's ARCT-021, says Piper
  • 28
    Jan
  • 14
    Aug
CVAC CureVac
$102.60 /

+6.61 (+6.89%)

CVAC CureVac
$102.60 /

+6.61 (+6.89%)

CVAC CureVac
$102.60 /

+6.61 (+6.89%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.